DURHAM – Cape Fear BioCapital has closed its inaugural venture fund at about $9 million to invest in early-stage North Carolina life-science companies.
The Durham-based firm has invested in seven companies and expects to add three to five more, general partner Ed Field told Triangle Business Journal. Cape Fear BioCapital launched in 2024 and has evaluated more than 225 North Carolina life-science companies over the past two years, according to Field.
The firm’s official website describes its focus as pre-seed and seed-stage investments in therapeutics companies rooted in North Carolina. It publicly lists six portfolio companies: Thoracic Innovations, Ten63 Therapeutics, Incyclix Bio, iOrganBio, EnFuego Therapeutics and Eldec Pharmaceuticals. The seventh investment reported by Field was not identified in the article.
A Form D filed with the Securities and Exchange Commission on May 21, 2024, identifies Cape Fear BioCapital Fund I, LP as a Durham venture-capital fund. The filing reported a $9.5 million offering, with $7.5 million sold at that time, and listed May 6, 2024 as the date of first sale.
Cape Fear BioCapital’s general partners are Field, Jimmy Melton and Dave Ousterout, according to the firm’s website.
Field told Triangle Business Journal that Cape Fear BioCapital expects to finish investing Fund I by mid-2027 and is considering a second fund with a target of $75 million to $100 million.
